Jim Keon
Jim Keon is the president of the Canadian Generic Pharmaceutical Association (CGPA), representing 17 companies in the generics industry. He has been vocal about the delays in Health Canada's approval process for generic drugs, highlighting the impact these delays have on both patients and the financial burden on public and private insurers.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 4.00 | 0.08% | +0% | 38,005,238 | 29,599 | $1,700,000 | 1,324$ |
| Totals | 1 | 38,005,238 | 29,599 | $1,700,000 | 1,324$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Jim Keon, president of industry group Biosimilars Canada, said the delays are threatening the financial viability of these products.
4
Canada:
Jim Keon, president of the CGPA, highlighted the resource shortages and increased submission volume affecting Health Canada's drug approval process.
6